MCID: ADL001
MIFTS: 39

Adult Lymphoma

Categories: Cancer diseases, Immune diseases, Neuronal diseases, Eye diseases

Aliases & Classifications for Adult Lymphoma

MalaCards integrated aliases for Adult Lymphoma:

Name: Adult Lymphoma 12 15 73

Classifications:



External Ids:

Disease Ontology 12 DOID:5825
NCIt 50 C7587
UMLS 73 C1332206

Summaries for Adult Lymphoma

MalaCards based summary : Adult Lymphoma is related to b-cell lymphomas and diffuse large b-cell lymphoma. An important gene associated with Adult Lymphoma is IFT172 (Intraflagellar Transport 172), and among its related pathways/superpathways are NF-kappaB Signaling and Hematopoietic cell lineage. The drugs Teniposide and rituximab have been mentioned in the context of this disorder. Affiliated tissues include b cells, t cells and bone, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Related Diseases for Adult Lymphoma

Diseases in the Lymphoma family:

Adult Lymphoma Eye Lymphoma

Diseases related to Adult Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 49)
# Related Disease Score Top Affiliating Genes
1 b-cell lymphomas 28.5 CD5 MYC PRDM1 TNFRSF8
2 diffuse large b-cell lymphoma 26.9 ALK CD5 MYC PRDM1 TNFRSF8
3 ovarian squamous cell carcinoma 10.6 CSF3 SMUG1
4 bone lymphoma 10.6 IFT172 SMUG1
5 prostate lymphoma 10.6 CD5 SMUG1
6 mediastinal cancer 10.5 CD5 SMUG1
7 pericardial tuberculosis 10.4 CABIN1 SMUG1
8 sternum cancer 10.3 SMUG1 TNFRSF8
9 epidural neoplasm 10.3 CD5 TNFRSF8
10 granulomatous myositis 10.3 SMUG1 TNFRSF8
11 immune system organ benign neoplasm 10.2 CD5 TNFRSF8
12 b cell prolymphocytic leukemia 10.2 CD5 MYC
13 poliomyelitis 10.2 FCGR2A FCGR3A
14 thymus lipoma 10.2 CD5 TNFRSF8
15 plasmablastic lymphoma 10.2 MYC PRDM1
16 rheumatic myocarditis 10.2 CD2 FCGR3A
17 reticulum cell sarcoma 10.2 CD2 TNFRSF8
18 chronic nk-cell lymphocytosis 10.1 CD2 FCGR3A
19 richter's syndrome 10.1 CD5 MYC
20 lymphoma 10.1
21 cryptococcosis 10.0 FCGR2A FCGR3A
22 lymphangiosarcoma 10.0 MYC SMUG1
23 follicular mucinosis 9.9 CD2 TNFRSF8
24 lemierre's syndrome 9.9 ALK SMUG1
25 hodgkin's lymphoma, lymphocytic depletion 9.8 ALK TNFRSF8
26 xanthogranulomatous pyelonephritis 9.7 ALK SMUG1
27 in situ pulmonary adenocarcinoma 9.7 ALK SMUG1
28 breast lymphoma 9.6 ALK CD5 SMUG1
29 myeloma, multiple 9.6 CSF3 MYC PRDM1 SMUG1
30 ecthyma 9.5 ALK CSF3 TNFRSF8
31 prolymphocytic leukemia 9.5 CD5 MYC
32 malignant histiocytosis 9.5 MYC TNFRSF8
33 colon lymphoma 9.5 ALK CD5 TNFRSF8
34 peripheral t-cell lymphoma 9.4 ALK CD5 TNFRSF8
35 intussusception 9.4
36 lymphoma, hodgkin, classic 9.4
37 hyperuricemia 9.4
38 mediastinitis 9.4
39 influenza 9.4
40 nodular lymphocyte predominant hodgkin lymphoma 9.4
41 reticulosarcoma 9.3 ALK TNFRSF8
42 respiratory system cancer 9.2 ALK MYC SMUG1
43 cell type cancer 9.2 ALK MYC SMUG1
44 lung lymphoma 9.0 ALK CD5 SMUG1 TNFRSF8
45 pediatric lymphoma 8.8 ALK FCGR3A SMUG1 TNFRSF8
46 lymphatic system cancer 8.7 ALK CD5 MYC TNFRSF8
47 ewing sarcoma 8.6 ALK CSF3 MYC TNFRSF8
48 hematologic cancer 7.9 ALK CD2 CD5 CSF3 MYC TNFRSF8
49 lymphoma, non-hodgkin, familial 7.4 ALK CD5 CSF3 FCGR3A MYC SMUG1

Graphical network of the top 20 diseases related to Adult Lymphoma:



Diseases related to Adult Lymphoma

Symptoms & Phenotypes for Adult Lymphoma

GenomeRNAi Phenotypes related to Adult Lymphoma according to GeneCards Suite gene sharing:

26 (show all 15)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-112 9.62 TNFRSF8
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-144 9.62 MYC
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-15 9.62 TNFRSF8
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-160 9.62 MYC
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-171 9.62 PRDM1
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-173 9.62 MYC
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-179 9.62 PRDM1
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-18 9.62 TNFRSF8
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-191 9.62 TNFRSF8 FCGR2A
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-26 9.62 MYC
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-34 9.62 FCGR2A
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-58 9.62 TNFRSF8
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-60 9.62 FCGR2A MYC PRDM1 TNFRSF8
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-66 9.62 FCGR2A PRDM1
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-87 9.62 FCGR2A

Drugs & Therapeutics for Adult Lymphoma

Drugs for Adult Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 962)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Teniposide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 29767-20-2 34698
2
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 174722-31-7 10201696
3
Gemcitabine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 95058-81-4 60750
4
Vidarabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 24356-66-9 32326 21704
5
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 135968-09-1
6
Fludarabine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 21679-14-1, 75607-67-9 30751
7
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 33419-42-0 36462
8
Menthol Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1 2216-51-5 16666
9
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 84093 441203 2767
10
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 23214-92-8 31703
11
Dasatinib Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 302962-49-8 3062316
12
Hydrocortisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-23-7 5754
13
Dacarbazine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 4342-03-4 5351166
14
Denileukin diftitox Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 173146-27-5
15
Vinblastine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 865-21-4 13342 241903
16
Mechlorethamine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-75-2 4033
17
Ifosfamide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 3778-73-2 3690
18
Tropisetron Approved, Investigational Phase 4,Not Applicable 105826-92-4, 89565-68-4 5595
19
Iron Approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1,Not Applicable 7439-89-6 23925
20
Aprepitant Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1 170729-80-3 151165 6918365
21
Dopamine Approved Phase 4,Phase 3,Phase 2,Not Applicable 51-61-6, 62-31-7 681
22
Clarithromycin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 81103-11-9 84029
23
Mesna Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 3375-50-6 598
24
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 2068-78-2, 57-22-7 5978
25
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 1959-05-2, 59-05-2 126941
26
Cytarabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 147-94-4 6253
27
Zidovudine Approved Phase 4,Phase 2,Not Applicable 30516-87-1 35370
28
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 22916-47-8 4189
29
Thiotepa Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 52-24-4 5453
30
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-18-0, 6055-19-2 2907
31
Metronidazole Approved Phase 4,Phase 3,Phase 2 443-48-1 4173
32
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-02-2 5743
33
Valproic Acid Approved, Investigational Phase 4,Phase 2,Phase 1,Early Phase 1 99-66-1 3121
34
Busulfan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 55-98-1 2478
35
Idarubicin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58957-92-9 42890
36
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-24-8 5755
37
Oxaliplatin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 61825-94-3 5310940 9887054 43805 6857599
38
Palonosetron Approved, Investigational Phase 4,Phase 2,Not Applicable 135729-61-2, 119904-90-4, 135729-56-5 148211
39
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 159351-69-6 6442177
40
Amoxicillin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 26787-78-0 33613
41
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 104987-11-3 445643 439492
42
Melphalan Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 148-82-3 4053 460612
43
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 24280-93-1 446541
44
Mitoxantrone Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 65271-80-9 4212
45
Bexarotene Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 153559-49-0 82146
46
Daunorubicin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 20830-81-3 30323
47
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1994-09-7, 94-09-7 2337
48
Amifostine Approved, Investigational Phase 4,Phase 2,Phase 1 20537-88-6 2141
49
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 128794-94-5 5281078
50
Granisetron Approved, Investigational Phase 4,Phase 2,Not Applicable 109889-09-0 3510

Interventional clinical trials:

(show top 50) (show all 6498)
# Name Status NCT ID Phase Drugs
1 Intensification Therapy of Mature B-ALL, Burkitt and Burkitt Like and Other High Grade Non-Hodgkin's Lymphoma in Adults Unknown status NCT00797810 Phase 4 Rituximab
2 Low Grade Lymphoma Unknown status NCT01698866 Phase 4
3 CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With PTCL Unknown status NCT02533700 Phase 4 CEOP/IVE/GDP chemotherapy regimen;CEOP chemotherapy regimen for 6 cycles
4 Optimization of the Primary Therapy for Patients With Hodgkin's Disease and Evaluation of PET Unknown status NCT00188149 Phase 4 Combined chemotherapy (ABVD, BACOPP-D)
5 Self-control Trial to Evaluate the Role of Aprepitant in the Prophylaxis of Post-lumbar-punture-headache (PLPH) Unknown status NCT02347878 Phase 4 Aprepitant
6 Study Comparing Sequential and Concomitant Therapy for Helicobacter Pylori Eradication in Routine Clinical Practice Unknown status NCT01273441 Phase 4 PPI, amoxicillin, metronidazole and clarithromycin;PPI, amoxicillin, metronidazole and clarithromycin
7 Low-dose Chemotherapy Combine With Tyrosine Kinase Inhibitor to Treat ph+ Acute Lymphoblastic Leukemia Patients Unknown status NCT02690922 Phase 4 Dasatinib;prednisone;dexamethasone;methotrexate
8 HD-Idarubicin/Etoposide Intensified Conditioning Regimen Allo-HSCT for Adult ALL Unknown status NCT01873807 Phase 4 IDA;CTX;VP-16
9 Medical Research Council (MRC) Working Party on Leukaemia in Children UK National Acute Lymphoblastic Leukaemia (ALL) Trial: UKALL 2003 Unknown status NCT00222612 Phase 4 Standard childhood UK ALL protocol;Intensified treatment including Capizzi maintenance
10 Poly(Ethylene Glycol)(PEG)-Asparaginase During Two Treatment Courses Unknown status NCT00192673 Phase 4 PEG-asparaginase
11 German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (07/2003) Unknown status NCT00198991 Phase 4 Cyclophosphamide;Dexamethasone;Vincristine;daunorubicin;Asparaginase;Methotrexate;Cytarabine;Mercaptopurine;G-CSF;Vindesine;VP16;Prednisolone;Adriamycin;Thioguanine;VM26;Idarubicin;Fludarabine;Cladribine
12 German Multicenter Trial for Treatment of Elderly Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Unknown status NCT00198978 Phase 4 Cyclophosphamide;Dexamethasone / Prednisolone;Cytarabine;Idarubicin;Granulocyte-Colony-Stimulating Factor;Mercaptopurine;Methotrexate;Rituximab;HDARAC;Vincristine;Depocyte;Asparaginase
13 Treatment Protocol of Children With Philadelphia Chromosome Negative High Risk Acute Lymphoblastic Leukemia Unknown status NCT01990807 Phase 4 Idarubicin(IDA)
14 Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer Unknown status NCT00274885 Phase 4 oxaliplatin
15 Zevalin® Followed by Rituxan® Maintenance in Previously Treated Low Grade Non-Hodgkin’s Lymphoma Completed NCT00168727 Phase 4 ibritumomab tiuxetan (Zevalin®)
16 An Open Label Treatment Use Protocol for Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma Completed NCT01833039 Phase 4 Ibrutinib
17 Treatment of Peripheral T-cell Lymphoma Completed NCT01664975 Phase 4 GDPT regimen;CHOP regimen
18 PEG-rhG-CSF in Patients With Lymphoma Receiving Chemotherapy Completed NCT02805218 Phase 4 PEG-rhG-CSF
19 MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma. Completed NCT00430352 Phase 4 rituximab [MabThera/Rituxan]
20 Study of ONTAK® to Treat Cutaneous T-Cell Lymphoma (CTCL) Completed NCT00211198 Phase 4 ONTAK (denileukin difitox, DAB389IL-2)
21 Study Evaluating Two Dose Levels of Targretin Capsules in Patients With Refractory Cutaneous T-cell Lymphoma (CTCL) Completed NCT01007448 Phase 4 bexarotene;bexarotene
22 Doxorubicin Pharmacokinetics and Response in Non Hodgkin's Lymphoma Completed NCT00969462 Phase 4 Doxorubicin
23 Evaluation of Approved Weight-Based Dose Compared to Fixed Dose of Plerixafor in Patients With Non-Hodgkin's Lymphoma (NHL) Weighing Less Than 70 Kilograms Completed NCT01164475 Phase 4 Granulocyte-colony stimulating factor (G-CSF);Fixed Dose Plerixafor;Weight-Based Plerixafor
24 German Multicenter Trial for the Treatment of Newly Diagnosed T-lymphoblastic Lymphoma in Adults Completed NCT00199017 Phase 4 Dexamethasone/Prednisolone;Cyclophosphamide;Vincristine;Daunorubicin;Asparaginase;G-CSF;Mercaptopurine;Cytarabine;Methotrexate;VP16;Vindesine;Adriamycin;Thioguanine;HDARAC;Cladribine
25 Efficacy Response Duration and Toxicity of Rituximab, Fludarabine, and Cyclophosphamide (RFC) as 1st Line Treatment and Rituximab (R) in Maintenance Treatment in Follicular Non Hodgkin (FNH) Lymphoma Completed NCT01124526 Phase 4 Rituximab Fludarabine Cyclophosphamide
26 Whole Brain Irradiation in Primary Central Nervous System (CNS) Lymphoma (PCNSL) Completed NCT00153530 Phase 4 methotrexate
27 Prophylactic Use of Entecavir for Non-Hodgkin's Lymphoma Patients With Resolved Hepatitis B Completed NCT00926757 Phase 4 Entecavir prophylaxis;Therapeutic entecavir
28 Carbohydrate Metabolism Disorder Frequency in Hypertriglyceridemia Induced by Bexarotene of Cutaneous T Cell Lymphoma Completed NCT01569724 Phase 4
29 An Expanded Access Program of Pegfilgrastim (Neulastim) in Participants With Non-Hodgkin's Lymphoma (NHL) Completed NCT02782845 Phase 4 Chemotherapy;Immunochemotherapy;Pegfilgrastim
30 LINFOTARGAM: Treatment With Chemotherapy Plus Rituximab and Highly Active Antiretroviral Therapy in Patients With Diffuse Large B Cell Lymphoma and Infection With the Human Immunodeficiency Virus (HIV) Completed NCT00466258 Phase 4 R-CHOP;Highly active antiretroviral therapy;Central nervous system (CNS) prophylaxis;Prophylaxis of opportunistic infections and support treatment
31 Study of ONTAK (Denileukin Diftitox) in Cutaneous T-Cell Lymphoma (CTCL) Patients Completed NCT00050999 Phase 4 ONTAK
32 Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients Completed NCT00051012 Phase 4 ONTAK
33 Effect of Rituximab on Immunological Recall Response to Specific Antigens in the Treatment of Non-Hodgkin's Lymphoma Completed NCT00090038 Phase 4 rituximab
34 Study of Rasburicase as Treatment or Prevention of Hyperuricemia Associated With Tumor Lysis Syndrome in Patients With Relapsed or Refractory Lymphoma, Leukemia, or Solid Tumor Malignancy Completed NCT00230217 Phase 4 Rasburicase (SR29142)
35 Trial for the Treatment of Newly Diagnosed Mature B-Cell Acute Lymphoblastic Leukemia (B-ALL), Burkitt's Non-Hodgkin's Lymphoma (NHL) and Other High-grade Lymphoma in Adults Completed NCT00199082 Phase 4 Adriamycin;Cyclophosphamide;Cytarabine;Dexamethasone/Prednisolone;VP16;Ifosfamide;Methotrexate;G-CSF;Rituximab;Vincristine/Vindesine
36 Prevention of CHOP-induced Chronic Cardiotoxicity Completed NCT00162955 Phase 4 Valsartan
37 Photopheresis as an Interventional Therapy for the Treatment of CTCL (Cutaneous T-Cell Lymphoma, Mycosis Fungoides) Stage 1A, 1B, 2A Completed NCT00221039 Phase 4 Methoxsalen+ECP
38 Pilot Study of Combination Therapy With CHOP-Zenapax (CHOP-daclizumab) Completed NCT01418430 Phase 4 CHOP-daclizumab
39 PROMPT - Palifermin in Reduction of Oral Mucositis in PBSC Transplantation Completed NCT00352703 Phase 4 Kepivance (Palifermin)
40 Epoetin Alfa (Hemax®) Phase IV Study in Chemotherapy Induced Anemia Completed NCT01374373 Phase 4
41 Effect of Epoetin Alfa on Hemoglobin, Symptom Distress, and Quality of Life in Patients Receiving Chemotherapy Completed NCT00524407 Phase 4 Epoetin alfa
42 Evaluation of the Analgesy With Emla and/or Nitrous Oxide in Pediatric Patients for Lumbar Puncture Completed NCT00808171 Phase 4 Livopan;Livopan;EMLA
43 ALL-REZ BFM 2002: Multi-Center Study for Children With Relapsed Acute Lymphoblastic Leukemia Completed NCT00114348 Phase 4
44 DepoCyt Therapy in Patients With Neoplastic Meningitis From Lymphoma or a Solid Tumor Completed NCT00029523 Phase 4 Intrathecal (injected into the spinal fluid) DepoCyt;Intrathecal methotrexate;Intrathecal cytarabine (also known as ara-C)
45 AMENO-2: Aprepitant Plus Palonosetron Versus Granisetron in the Prevention of Nausea and the Emesis Induced by Chemotherapy in Patients Treated With Haematopoietic Progenitors Completed NCT00415103 Phase 4 Aprepitant;Palonosetron;Granisetron
46 A Study of Primary Prophylaxis With Neulasta (Pegfilgrastim) Versus Secondary Prophylaxis After Chemotherapy in Elderly Subjects (>/= 65 Years Old) With Cancer Completed NCT00277160 Phase 4 Neulasta (pegfilgrastim)
47 10-day Versus 14-day Concomitant PAMC as First-line Treatment Strategy for the Eradication of H. Pylori Infection Completed NCT02959255 Phase 4 Esomeprazole
48 Subcutaneous Amifostine Safety Study Completed NCT00158041 Phase 4 Amifostine administered subcutaneously
49 Intraluminal Therapy for Helicobacter Pylori Infection Completed NCT03124420 Phase 4 Lansoprazole;Amoxicillin;Clarithromycin
50 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa

Search NIH Clinical Center for Adult Lymphoma

Genetic Tests for Adult Lymphoma

Anatomical Context for Adult Lymphoma

MalaCards organs/tissues related to Adult Lymphoma:

41
B Cells, T Cells, Bone, Bone Marrow, Lung, Myeloid, Breast

Publications for Adult Lymphoma

Articles related to Adult Lymphoma:

(show all 19)
# Title Authors Year
1
Adolescent and young adult lymphoma: collaborative efforts toward optimizing care and improving outcomes. ( 29296842 )
2017
2
Building a Healthy Body After Cancer: Young Adult Lymphoma Survivors' Perspectives on Exercise After Cancer Treatment. ( 29272188 )
2017
3
Hybrid FDG-PET/MR compared to FDG-PET/CT in adult lymphoma patients. ( 27315095 )
2016
4
Successful management of adult lymphoma-associated intussusception by laparoscopic reduction and appendectomy. ( 27217710 )
2016
5
Changing trends of adult lymphoma in the kingdom of saudi arabia - comparison of data sources. ( 25773852 )
2015
6
Obesity in adult lymphoma survivors. ( 21888618 )
2012
7
Nodular, lymphocyte-predominant Hodgkin lymphoma: a long-term study and analysis of transformation to diffuse large B-cell lymphoma in a cohort of 164 patients from the Adult Lymphoma Study Group. ( 20029973 )
2010
8
Ophthalmic disorders in adult lymphoma patients. ( 21180448 )
2010
9
Efficacy and toxicity of 2 schedules of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone plus bortezomib in patients with B-cell lymphoma: a randomized phase 2 trial from the French Adult Lymphoma Study Group (GELA). ( 19593797 )
2009
10
Ophthalmic disorders in adult lymphoma patients in Africa. ( 20404992 )
2009
11
Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: results of the GRAAL1 (Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma) study. ( 14581437 )
2003
12
Comparison of echocardiography and radionuclide ventriculography in the follow-up of left ventricular systolic function in adult lymphoma patients during doxorubicin therapy. ( 11298849 )
2001
13
Neuroendocrine changes during the evolution of doxorubicin-induced left ventricular dysfunction in adult lymphoma patients. ( 11724646 )
2001
14
CyclOBEAP (cyclophosphamide, vincristine, bleomycin, etoposide, doxorubicin, prednisolone) regimen with granulocyte colony-stimulating factor (G-CSF) for patients with aggressive non-Hodgkin's lymphoma: a pilot study. The Adult Lymphoma Treatment Study Group (ALTSG). ( 11007055 )
2000
15
Beyond cancer: changes, problems and needs expressed by adult lymphoma survivors attending an out-patients clinic. ( 7711981 )
1994
16
Does treatment with haemopoietic growth factors affect the incidence of bacteraemia in adult lymphoma transplant recipients? ( 7687501 )
1993
17
Antibody response to a two-dose influenza vaccine regimen in adult lymphoma patients on chemotherapy. ( 8307050 )
1993
18
Mediastinal large cell lymphoma. An uncommon subset of adult lymphoma curable with combined modality therapy. ( 3167803 )
1988
19
Clinical utility of lymphocyte surface markers combined with the Lukes-Collins histologic classification in adult lymphoma. ( 313510 )
1979

Variations for Adult Lymphoma

Expression for Adult Lymphoma

Search GEO for disease gene expression data for Adult Lymphoma.

Pathways for Adult Lymphoma

Pathways related to Adult Lymphoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 12.07 CABIN1 CD2 PRDM1 TNFRSF8
2 11.32 CD2 CD5 CSF3
3 10.99 CD2 CD5 CSF3 FCGR2A
4 10.86 CD5 PRDM1 TNFRSF8

GO Terms for Adult Lymphoma

Biological processes related to Adult Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 regulation of cell proliferation GO:0042127 8.8 ALK PRDM1 TNFRSF8

Molecular functions related to Adult Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 IgG binding GO:0019864 8.62 FCGR2A FCGR3A

Sources for Adult Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....